Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

District court upholds herbal extract patents

This article was originally published in The Tan Sheet

Executive Summary

Herbal extract firm Sabinsa Corp. retains exclusive proprietary rights to BioPerine (piperine black pepper extract) and Forslean (coleus forkskohlii), the U.S. District Court for the District of New Jersey says in a June 27 final judgment against DNP International. The ruling upholds the validity and enforceability of the '382, '596 and '712 patents pertaining to Sabinsa's products. DNP agreed to discontinue importing, manufacturing and/or marketing piperine, coleus and coleus oil for sale in the United States. Sabinsa sued DNP for patent infringement because it marketed and distributed piperine and coleus for uses previously researched and patented by Sabinsa in the late 1960s, the company says. Piscataway, N.J.-based Sabinsa manufactures Phytonutrients and Ayurvedic herbal extracts for nutritional, pharmaceutical and food products...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel